Skip to main content

Cost-effectiveness of Erenumab Versus Surgical Trigger Site Deactivation for the Treatment of Migraine Headaches: A Systematic Review - PubMed

Cost-effectiveness of Erenumab Versus Surgical Trigger Site Deactivation for the Treatment of Migraine Headaches: A Systematic Review - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33710044/

doi: 10.1097/SCS.0000000000007617. Online ahead of print. 1 Northwestern University Feinberg School of Medicine, Chicago, IL Department of Plastic Surgery Department of Neurology, University of California, Irvine School of Medicine, Orange, CA. doi: 10.1097/SCS.0000000000007617. Online ahead of print. 1 Northwestern University Feinberg School of Medicine, Chicago, IL Department of Plastic Surgery Department of Neurology, University of California, Irvine School of Medicine, Orange, CA.

  • from Doctor Unite 2 weeks 4 days
    Another thing to consider are the risks, complications, and comorbidities for the surgical treatment. Would there be a need for second surgeries? Would the patient still require medications even after surgery?
  • 2 weeks 5 days
    I find this study quite misleading on several fronts:
    1. The data to support surgical trigger site deactivation for migraine is quite limited and biased
    2. The estimates for the direct cost for episodic and chronic migraine were quite a large range and higher than those that I have seen in the past
    3. Even with surgical treatment, there are still annual direct costs because these individuals do not become headache free
    Therefore, I would hope that this article does not convince providers to consider an invasive and marginally effective therapy such as surgery without trying well established effective, well tolerated medical treatments such as CGRP mab
  • 1 month
    This lists the prices but this should also be compared to the efficacy of the two treatments.